| Family: | State Street (SPDR) |
| Name: | SPDR S&P Biotech ETF |
| Inception Date: | 31-Jan-2006 |
| Termination Date: | |
| Investment Objective: | The SPDR S&P Biotech ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index (the Index ). The S&P Biotechnology Select Industry represents the biotechnology segment of the S&P Total Market Index ( S&P TMI ). The S&P TMI is designed to track the broad U.S. equity market. The biotechnology segment of the S&P TMI comprises the Biotechnology sub-industry. The Index is modified equal weighted. |
| Prospectus | |
| Top 10 Holdings | ||
| APELLIS PHARMACEUTICALS INC | APLS | 1.8377% |
| MADRIGAL PHARMACEUTICALS INC | MDGL | 1.3982% |
| ALKERMES PLC | ALKS | 1.3871% |
| TG THERAPEUTICS INC | TGTX | 1.3575% |
| INSMED INC | INSM | 1.3282% |
| SCHOLAR ROCK HOLDING CORP | SRRK | 1.2776% |
| APOGEE THERAPEUTICS INC | APGE | 1.2714% |
| TWIST BIOSCIENCE CORP | TWST | 1.2346% |
| TRAVERE THERAPEUTICS INC | TVTX | 1.2158% |
| SUMMIT THERAPEUTICS INC | SMMT | 1.2134% |
| Top 10 Holdings Weight: | 13.5% |
| Number of Holdings: | 157 |
| Shares Outstanding: | 63,700,000 |
| Total Net Assets: | 8,204,560,000 |
| NAV: | 128.76 |
| Net Expense Ratio: | 0.35% |
| Asset Class: | Equities (Stocks) |
| Developed or Emerging: | Developed Market Funds |
| Country: | US |
| Region: | |
| Strategy: | |
| Currency: | |
| Commodity: | |
| Sector: | Healthcare |
| Industry: | Biotech |
| Dividend Type: | |
| Tax Exempt State: | |
| Maturity Duration: | |
| Market Cap: | Broad Market / Multi-Cap |
| Credit Quality: | |
| Mortgage Bond Types: | |
| Bond Type: | |
| Gov't Bond Types: | |
| Reit Type: | |
| Leverage Direction/Factor: | |
| Is Currency Hedged: | No |
| US or Ex-US: | Domestic |
